Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Tuesday 17 November, 2009


UCB plans organizational changes in Braine-l'Al...

Brussels (Belgium) - November 17, 2009 - Press Release - UCB
announced today its intention to make organizational changes in some
divisions at its sites in Braine-l'Alleud (Belgium) and Slough (UK).
The main purpose of this project is to optimize the transformation of
UCB into a biopharma leader with the ambition to realize sustainable
growth for the years to come.

Both Braine-l'Alleud and Slough are key strategic sites and play a
pivotal role in UCB's biopharma strategy. At both the Braine-l'Alleud
and Slough sites, UCB intends to adapt its NewMedicines division;
additionally on the Braine-l'Alleud site, the company intends to
streamline manufacturing support services, industrial development and
some administrative functions. In this way, UCB aims to broaden its
biotechnological capability in line with new product and pipeline
requirements. The project also takes into account the need to invest
in newly launched products while maintaining profitability following
patent expiries.

UCB today informed its employees and employee representatives of the
proposed projects that could impact 174 positions in Braine-l'Alleud
and 44 positions in Slough and is subject to the information and
consultation procedures which apply in Belgium and the UK. In
parallel a series of new functions could also be created to meet new
biopharma profiles and allow UCB to pursue its transformation.

"UCB's ability to adapt is key to maintaining our competitiveness
within the world of biopharma innovation'' said Roch Doliveux, CEO of
UCB. "We will help our employees to go through the changes ahead of
us and I commit to an open and constructive dialogue with our social
partners. Our priority will be to look for solutions that lead to a
new future."

Pictures available for download at

For further information
Nancy Nackaerts, External Communications, UCB
T +32 (0)473.864.414, ,  [email protected]

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, [email protected]

Cindy Maas, External Communications, UCB
T +32 (0)495.588.377, [email protected]

About NewMedicines(TM)
Encompassing discovery research activities through to proof of
concept, UCB NewMedicines(TM) is an innovative and externally
networked organisation established to secure the future pipeline and
deliver UCB's breakthrough products of the future.
A disseminated research organisation will maximise UCB's investment
in scientific and medical breakthroughs via a highly collaborative
approach to forming teams and projects to create new medicines. Based
on a 'hub' model of operation, UCB NewMedicines(TM) is located on two
key sites at Braine-l'Alleud, Belgium and Slough, UK. Operations at
these hubs focus on the therapeutic areas of CNS (Central Nervous
System) and Immunology with strong technology platforms underpinning
the research. The organisation houses leaders and experts who possess
the highest level skills to search, review, decide and transact on
all aspects of the portfolio in all functions.
Internal resources differentiate UCB whilst external resources are
accessed for routine activities or to provide specialist
complementary skills and capabilities. The organisation fully
embraces external networking to support our focus on the pipeline
delivery and breakthrough science.  Medics and patients inform
choices from the outset of projects.

About UCB
UCB, Brussels, Belgium (  is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of EUR 3.6 billion
in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

For the pdf-version of this press release, please click on the link

This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


a d v e r t i s e m e n t